Cite
MLA Citation
Ian W. Flinn et al.. “Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study.” American journal of hematology, vol. 93, no. 11, n.d., pp. 1311–1317. http://access.bl.uk/ark:/81055/vdc_100070818850.0x00003d